New Launch24 Oct 2025, 07:31 pm
Zydus Lifesciences Receives Approval from Health Canada for Mesalamine Suppositories
AI Summary
Zydus Lifesciences Limited has received a Notice of Compliance (NOC) from Health Canada for generic Mesalamine suppositories 1000 mg. The suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis and will be manufactured at Zydus Lifesciences Ltd. Changodar, Ahmedabad in Gujarat, India. Mesalamine suppositories had annual sales of 4.86 mn CAD in Canada (IQVIA MAT June 2025).
Key Highlights
- Zydus Lifesciences receives approval from Health Canada for Mesalamine suppositories
- Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
- ZDS - Mesalamine suppositories will be manufactured at Zydus Lifesciences Ltd. Changodar, Ahmedabad in Gujarat, India
- Mesalamine suppositories had annual sales of 4.86 mn CAD in Canada (IQVIA MAT June 2025)